CCA
AXSM icon

Cygnus Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Cygnus Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33
Closed -$6 – 125
2025
Q4 		$6 Buy
+33
New +$4.61K ﹤0.01% 128

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cygnus Capital Advisors's AXSM Position: Q1 2026 in Review

Cygnus Capital Advisors sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 33 shares — an estimated $6 sold.

Cygnus Capital Advisors first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $6 in Q4 2025. 410 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Cygnus Capital Advisors reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 33 Axsome Therapeutics shares in Q1 2026, an estimated $6.
  • Cygnus Capital Advisors first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cygnus Capital Advisors's Axsome Therapeutics position peaked at $6 in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.